Mesoblast Limited vs Clear Secure Inc — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Clear Secure Inc trades at $56.69 (market cap $5.76B). The key difference: Clear Secure Inc is far larger — about 2.7× Mesoblast Limited's market cap, and Clear Secure Inc pays a 1.05% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | YOU | |
|---|---|---|
Market Cap | $2.17B | $5.76B |
Sector | Technology | Technology |
52-Week High | $20.96 | $62.36 |
52-Week Low | $12.88 | $28.84 |
Enterprise Value | $2.17B | $5.07B |
Dividend Yield | — | 1.05% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Clear Secure (YOU) trades at $57.18, up 2.05% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and impressive 81.15% ROE, though valuation multiples remain elevated with a P/E of 44.82. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected, while analyst sentiment remains divided with equal buy/hold ratings.
The stock presents growth potential with expanding revenue and profitability, but faces valuation concerns and competitive pressures. Key catalysts include continued airport expansion and AWS partnership, while risks involve execution challenges and market volatility. The consensus price target of $56.67 suggests limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →